DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hypoparathyroidism", "Accessory thyroid hypergasia disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 100mcg rhPTH(1-84); 25mcg rhPTH(1-84); 50mcg rhPTH(1-84); A: PTH (1-84); Acetate; Alfacalcidol; Amorphous calcium carbonate; Betamethasone; CLTX-305; Calcitriol; Calcitriol & Calcium; Calcium; Calcium Carbonate; Calcium Citrate; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium citrate; Calcium gluconate; Calcium lactate; Carbonate; Combination Product: TransCon PTH; Combination product (Natpara) and drug or supplements [Disease and drug registry]; Crystalline calcium supplements; Dexamethasone; Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).; Diagnostic Test: Postoperative laboratory blood tests at 24 hour; Diagnostic Test: Postoperative laboratory blood tests at 6 hour; Diagnostic Test: Postoperative laboratory drainage fluid tests at 24 hour; Diagnostic Test: Preoparative blood laboratory tests; EB612 (EBP05); ESIDREX-R; ESIDREX-R 25 mg; EnteraBio's Oral Parathyroid Hormone (1-34); Esidrex; Ether; FORSTEO; FORSTEO-R; Forsteo; Human recombinant parathyroid Hormone; Human recombinant parathyroid hormone; Hydrochlorothiazide; INDOCYANINE GREEN; INN Parathyroid Hormone (1-84) human; Immediate post operative bioassay of Parathyroid Hormone; Indocyanine Green; Indocyanine green; Magnesium; NATPARA/NATPAR; NPSP 558; NPSP558; Natpar; Natpara; Open-label PTH(1-84); Other: Empiric use of Calcium Carbonate and Calcitriol; Other: PTH based Calcium Carbonate and Calcitriol repletion; Other: Postoperative nausea and vomiting at 24 hour; Other: Postoperative nausea and vomiting at 6 hour; Other: Postoperative pain at 24 hour; Other: Postoperative pain at 6 hour; Other: Postoperative sore throat and hoarseness at 24 hour; Other: Postoperative sore throat and hoarseness at 6 hour; Other: Serum calcium concentrations results; Other: Symptomatic hypocalcaemia at 24 hour; Other: Symptomatic hypocalcaemia at 6 hour; PARATHYROID HORMONE; PCO371; POLY(OXY-1,2-ETHANEDIYL), A; POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DIOXO-3-PYRROLIDINYL]THIO]HEXYL]AMINO]ETHYL]AMINO]CARBONYL]-2-METHYLALANYL-TERIPARATIDE (2:1); PREOTACT; PTH; PTH 1-34; PTH1-84 in parent study; Parathyroid; Parathyroid Hormone; Parathyroid Hormone (1-84) Human Recombinant; Parathyroid Hormone (rDNA); Parathyroid hormon 1-84; Parathyroid hormone; Parathyroid hormone (rdna); Parathyroideahormon; Phosphate; Phosphate and betamethasone acetate, 2 mL.; Polyethylene glycol; Potassium; Potassium sparing diuretic; Preotact; Procedure: Total thyroidectomy; RECOMBINANT HUMAN PARATHYROID HORMONE (1-84); Rcombinant Human Parathyroid Hormone [rhPTH(1-84)]; Recombinant Human Parathyroid Hormone [rhPTH(1-84)]; RhPTH; RhPTH (1-84); RhPTH(1-84); SUB21634; Saline 0.9% NaCl; Sevelamer; Sodium citrate; Synthetic Human Parathyroid Hormone 1-34; TERIPARATIDE; Teriparatide; Teriparatide conjugated to a multiarm polyethylene glycol carrier molecule through a cleavable linker; Thiazide; Thymus/Parathyroid Transplantation; TransCon PTH; TransCon PTH high-dose pen; TransCon PTH low-dose pen; TransCon PTH mid-dose pen; Tériparatide; UN-ALPHA-R; UN-ALPHA-R 0.25µg; Verde de Indocianina (Indocyanine Green); Vitamin D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02824718 (ClinicalTrials.gov)	June 6, 2017	1/7/2016	Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism	A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism	Autosomal Dominant Hypocalcemia or OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment	Drug: Teriparatide;Drug: Thiazide;Drug: Potassium sparing diuretic;Drug: Alfacalcidol	Assistance Publique - Hôpitaux de Paris	Ministry of Health, France	Recruiting	18 Years	80 Years	All	12	Phase 2	France
2	EUCTR2016-000500-29-FR (EUCTR)	03/06/2016	26/04/2016	A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia	A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia - ACTICAS	Autosomal dominant hypocalcemia (ADH) MedDRA version: 19.0;Level: PT;Classification code 10021041;Term: Hypoparathyroidism;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: FORSTEO -R Product Name: FORSTEO -R INN or Proposed INN: Tériparatide Other descriptive name: FORSTEO -R Trade Name: ESIDREX -R 25 mg Product Name: ESIDREX -R 25 mg INN or Proposed INN: Hydrochlorothiazide Other descriptive name: ESIDREX -R Trade Name: UN-ALPHA-R 0.25µg Product Name: UN-ALPHA-R 0.25µg INN or Proposed INN: Alfacalcidol Other descriptive name: UN-ALPHA-R	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Not Recruiting			Female: yes Male: yes	25	Phase 2	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02824718
(ClinicalTrials.gov)

June 6, 2017

1/7/2016

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism

Autosomal Dominant Hypocalcemia or OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment

Drug: Teriparatide;Drug: Thiazide;Drug: Potassium sparing diuretic;Drug: Alfacalcidol

Assistance Publique - Hôpitaux de Paris

Ministry of Health, France

Recruiting

18 Years

80 Years

All

Phase 2

France

EUCTR2016-000500-29-FR
(EUCTR)

03/06/2016

26/04/2016

A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia

A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia - ACTICAS

Autosomal dominant hypocalcemia (ADH)
MedDRA version: 19.0;Level: PT;Classification code 10021041;Term: Hypoparathyroidism;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Trade Name: FORSTEO -R
Product Name: FORSTEO -R
INN or Proposed INN: Tériparatide
Other descriptive name: FORSTEO -R
Trade Name: ESIDREX -R 25 mg
Product Name: ESIDREX -R 25 mg
INN or Proposed INN: Hydrochlorothiazide
Other descriptive name: ESIDREX -R
Trade Name: UN-ALPHA-R 0.25µg
Product Name: UN-ALPHA-R 0.25µg
INN or Proposed INN: Alfacalcidol
Other descriptive name: UN-ALPHA-R

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France